Cite
Numbers needed to treat or harm and likelihood of being helped versus harmed for fremanezumab in patients who had prior inadequate response to two to four classes of migraine preventive medications: A post hoc analysis.
MLA
Ashina, Messoud, et al. “Numbers Needed to Treat or Harm and Likelihood of Being Helped versus Harmed for Fremanezumab in Patients Who Had Prior Inadequate Response to Two to Four Classes of Migraine Preventive Medications: A Post Hoc Analysis.” Headache: The Journal of Head & Face Pain, vol. 63, no. 10, Nov. 2023, pp. 1351–58. EBSCOhost, https://doi.org/10.1111/head.14651.
APA
Ashina, M., Mitsikostas, D. D., Ramirez, C. V., Barash, S., Ning, X., & Diener, H. (2023). Numbers needed to treat or harm and likelihood of being helped versus harmed for fremanezumab in patients who had prior inadequate response to two to four classes of migraine preventive medications: A post hoc analysis. Headache: The Journal of Head & Face Pain, 63(10), 1351–1358. https://doi.org/10.1111/head.14651
Chicago
Ashina, Messoud, Dimos D. Mitsikostas, Campos, Verena Ramirez, Steve Barash, Xiaoping Ning, and Hans‐Christoph Diener. 2023. “Numbers Needed to Treat or Harm and Likelihood of Being Helped versus Harmed for Fremanezumab in Patients Who Had Prior Inadequate Response to Two to Four Classes of Migraine Preventive Medications: A Post Hoc Analysis.” Headache: The Journal of Head & Face Pain 63 (10): 1351–58. doi:10.1111/head.14651.